Developer docs
API playgroundTry for free, no card

Search company profiles

Adrenomed

Full company profile

uuid0002gx6

Namestring
Adrenomed
Legal namestring
AdrenoMed AG
Websiteurl
adrenomed.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Adrenomed AG is a privately-financed, clinical-stage biopharmaceutical company founded in 2009 and headquartered in Hennigsdorf near Berlin, Germany. The company is developing enibarcimab (INN, formerly Adrecizumab/HAM8101), a first-in-class non-neutralizing monoclonal antibody that targets Adrenomedullin (ADM), an endogenous vasoprotective peptide regulator of vascular integrity. Its lead indication is septic shock, a life-threatening condition driven by loss of endothelial barrier function with reported mortality of 30–50% and no approved causative therapy. Adrenomed applies a biomarker-guided precision medicine approach, using bio-ADM (biologically active Adrenomedullin) and DPP3 (Dipeptidylpeptidase-3) to stratify patients most likely to benefit from treatment and exclude those with competing disease mechanisms.

Enibarcimab's mechanism is differentiated from neutralizing antibody approaches: rather than blocking ADM, it binds and traps ADM in the circulation while preserving its barrier-protective functionality, stabilizing endothelial cell junctions and reducing vascular leakage. Clinical proof-of-concept was established in the AdrenOSS-2 Phase II trial of 301 patients conducted in Germany, Belgium, France, and the Netherlands, which demonstrated a >60% relative reduction in 28-day all-cause mortality versus placebo in the biomarker-defined subgroup and a sustained benefit over three months, with results published in journals including The Lancet, Journal of Critical Care, Shock, and BMJ Open. The company has also explored enibarcimab in an investigator-initiated Phase II COVID-19 trial at University Medical Center Eppendorf (UKE Hamburg) and identified acute decompensated heart failure as a potential follow-on indication.

Adrenomed is pre-revenue and its economics are tied to clinical and regulatory milestones rather than product sales. The company has raised approximately EUR 46 million in equity across a 2018 Series D (EUR 24 million) and 2020 Series E (EUR 22 million), both co-led by Wellington Partners and HBM Healthcare Investments, supplemented by EUR 7.4 million in non-dilutive BMBF funding in 2022 and backing from KfW, Brandenburg Kapital, Hinkel, and the DBI fund. Its go-to-market targets hospital intensive care units globally, with regulatory engagement aligned to both the U.S. FDA (Fast Track designation granted April 2024) and European EMA (positive Scientific Advice December 2021). The company is preparing for a pivotal Phase III trial (BOOST) with biomarker-guided registration design and, post-approval, intends to commercialize through standard pharmaceutical distribution to hospital pharmacies and ICU settings, supported by a companion bio-ADM diagnostic co-developed with sphingotec GmbH.

Short descriptiontext

Adrenomed AG is a privately-financed German clinical-stage biopharmaceutical company developing enibarcimab, a first-in-class non-neutralizing monoclonal antibody targeting Adrenomedullin to restore vascular integrity in septic shock patients using a biomarker-guided precision medicine approach.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHennigsdorf, Germany
HQ citystring
Hennigsdorf
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
septic shock therapy, monoclonal antibody, vascular integrity, biomarker-guided medicine, critical care biopharmaceuticals
Industry3 codes
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAFAC
DMPK / ADME & Bioanalysis
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
Product category
Critical Care Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical product revenue
TypeOne Time License
Description

Pre-revenue clinical-stage company. Enibarcimab is in late-stage clinical development for septic shock. Revenue will be generated from pharmaceutical product sales upon regulatory approval. The company is preparing for pivotal Phase III trial (BOOST) following positive FDA and EMA regulatory feedback.

adrenomed.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Adrenomed is developing enibarcimab, a clinical-stage first-in-class non-neutralizing monoclonal antibody that binds and stabilizes Adrenomedullin (ADM) in circulation to restore and protect vascular integrity. The product targets critically ill patients with septic shock and other conditions driven by vascular leakage, with patient selection guided by a dual-biomarker (bio-ADM and DPP3) precision medicine approach. The company is currently pre-revenue and preparing for a pivotal Phase III (BOOST) trial after FDA Fast Track designation in April 2024.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • >60% relative reduction in 28-day mortality vs placebo in biomarker-defined (bio-ADM and DPP3) target population with sustained effect over 3 months
+3 more records
Product overview1 text field

Adrenomed is a clinical-stage biopharmaceutical company developing a single lead product candidate: enibarcimab (INN, formerly Adrecizumab, HAM8101). This first-in-class monoclonal antibody targets Adrenomedullin to treat life-threatening conditions associated with loss of vascular integrity, with septic shock as the primary indication. The company employs a biomarker-guided precision medicine approach using bio-ADM (biologically active Adrenomedullin) and DPP3 (Dipeptidylpeptidase 3) to identify patients most likely to benefit from treatment. The product does not fit a traditional SaaS platform-plus-modules architecture; it is a biologic drug therapeutic.

Product and service1 record
1Enibarcimab (HAM8101, formerly Adrecizumab)
CategorySepsis and septic shock biologic therapy
Description

A clinical-stage, first-in-class non-neutralizing monoclonal antibody targeting Adrenomedullin (ADM) that binds and stabilizes ADM in circulation to restore vascular integrity in critically ill patients with septic shock and other conditions associated with increased vascular leakage. Administered as a single dose and being developed with a biomarker-guided precision medicine approach using bio-ADM and DPP3. Targeted at hospitals, ICUs, and acute care providers treating septic shock patients.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2022-04-11
Description

UKE Hamburg is conducting an investigator-initiated Phase II clinical trial with Adrecizumab (enibarcimab) in hospitalized COVID-19 patients with elevated adrenomedullin levels and endothelial barrier dysfunction. Prof. Dr. med. Stefan Kluge, Director of Department of Intensive Care Medicine at UKE, is leading the study.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership for biomarker development and diagnostics. sphingotec developed sphingotest bio-ADM for measuring biologically active Adrenomedullin and co-hosts international scientific symposiums on vascular integrity with Adrenomed. Both companies founded by Dr. Andreas Bergmann. bio-ADM biomarker used for patient stratification in AdrenOSS-2 and upcoming pivotal trials. sphingotec is developing point-of-care solution on Nexus IB10 platform for bio-ADM measurement.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Inotrem
TypeDirect peer
Description

Inotrem is a clinical-stage biotech developing nangibotide, a TREM-1 inhibitor for septic shock, pursuing a similar precision-medicine biomarker strategy targeting immune/vascular dysregulation in critically ill ICU patients.

TypeDirect peer
Description

AM-Pharma is a clinical-stage biopharmaceutical company developing recombinant human alkaline phosphatase for the treatment of sepsis-associated acute kidney injury, targeting the same ICU/septic shock patient population as enibarcimab.

TypeDirect peer
Description

InflaRx is a clinical-stage biopharmaceutical company developing vilobelimab, an anti-C5a monoclonal antibody for severe COVID-19, hidradenitis suppurativa, and other inflammatory indications, including sepsis-related applications.

TypeDirect peer
Description

Atox Bio is a late-stage clinical biotech developing AB103, a peptide therapeutic targeting the immune dysregulation pathway in necrotizing soft tissue infections and sepsis, with comparable septic shock development focus.

TypeDirect peer
Description

Endpoint Health is a precision-medicine clinical-stage company developing targeted therapies for immune-driven critical illness including sepsis and septic shock, sharing the biomarker-guided patient selection paradigm.

TypeEmerging player
Description

Enlivex Therapeutics is a clinical-stage company developing Allocetra, a cell therapy for sepsis and other inflammatory conditions, representing an alternative immunomodulatory approach to septic shock treatment.

TypeOthers
Description

sphingotec is a diagnostics company developing the bio-ADM biomarker assay used in Adrenomed's patient stratification; co-founded by Adrenomed's co-founder, making it a strategic ecosystem partner and supplier of the companion diagnostic.

TypeBroad incumbent
Description

Shionogi is a Japanese pharmaceutical company with established anti-infectives franchise (including cefiderocol) and active sepsis/critical-care portfolio, representing a potential large-pharma acquirer or commercial partner for enibarcimab.

TypeEmerging player
Description

CytoDyn is a clinical-stage biotechnology company that has investigated leronlimab (anti-CCR5 mAb) in sepsis-related indications, representing a comparable small-cap clinical-stage sepsis therapeutics developer.

10Adrenomed's sphingotest bio-ADM diagnostic
TypeOthers
Description

The bio-ADM (biologically active Adrenomedullin) assay from sphingotec is the diagnostic companion that stratifies septic shock patients for enibarcimab treatment; it is the enabling technology for Adrenomed's precision-medicine approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Adrenomed

Critical Care Biopharmaceuticalsadrenomed.com

Adrenomed AG is a privately-financed German clinical-stage biopharmaceutical company developing enibarcimab, a first-in-class non-neutralizing monoclonal antibody targeting Adrenomedullin to restore vascular integrity in septic shock patients using a biomarker-guided precision medicine approach.

What Adrenomed does

Adrenomed AG is a privately-financed, clinical-stage biopharmaceutical company founded in 2009 and headquartered in Hennigsdorf near Berlin, Germany. The company is developing enibarcimab (INN, formerly Adrecizumab/HAM8101), a first-in-class non-neutralizing monoclonal antibody that targets Adrenomedullin (ADM), an endogenous vasoprotective peptide regulator of vascular integrity. Its lead indication is septic shock, a life-threatening condition driven by loss of endothelial barrier function with reported mortality of 30–50% and no approved causative therapy. Adrenomed applies a biomarker-guided precision medicine approach, using bio-ADM (biologically active Adrenomedullin) and DPP3 (Dipeptidylpeptidase-3) to stratify patients most likely to benefit from treatment and exclude those with competing disease mechanisms.

Enibarcimab's mechanism is differentiated from neutralizing antibody approaches: rather than blocking ADM, it binds and traps ADM in the circulation while preserving its barrier-protective functionality, stabilizing endothelial cell junctions and reducing vascular leakage. Clinical proof-of-concept was established in the AdrenOSS-2 Phase II trial of 301 patients conducted in Germany, Belgium, France, and the Netherlands, which demonstrated a >60% relative reduction in 28-day all-cause mortality versus placebo in the biomarker-defined subgroup and a sustained benefit over three months, with results published in journals including The Lancet, Journal of Critical Care, Shock, and BMJ Open. The company has also explored enibarcimab in an investigator-initiated Phase II COVID-19 trial at University Medical Center Eppendorf (UKE Hamburg) and identified acute decompensated heart failure as a potential follow-on indication.

Adrenomed is pre-revenue and its economics are tied to clinical and regulatory milestones rather than product sales. The company has raised approximately EUR 46 million in equity across a 2018 Series D (EUR 24 million) and 2020 Series E (EUR 22 million), both co-led by Wellington Partners and HBM Healthcare Investments, supplemented by EUR 7.4 million in non-dilutive BMBF funding in 2022 and backing from KfW, Brandenburg Kapital, Hinkel, and the DBI fund. Its go-to-market targets hospital intensive care units globally, with regulatory engagement aligned to both the U.S. FDA (Fast Track designation granted April 2024) and European EMA (positive Scientific Advice December 2021). The company is preparing for a pivotal Phase III trial (BOOST) with biomarker-guided registration design and, post-approval, intends to commercialize through standard pharmaceutical distribution to hospital pharmacies and ICU settings, supported by a companion bio-ADM diagnostic co-developed with sphingotec GmbH.

Adrenomed firmographics

Firmographics
Name
Adrenomed
Legal name
AdrenoMed AG
Website
https://adrenomed.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
Adrenomed AG is a privately-financed German clinical-stage biopharmaceutical company developing enibarcimab, a first-in-class non-neutralizing monoclonal antibody targeting Adrenomedullin to restore vascular integrity in septic shock patients using a biomarker-guided precision medicine approach.
Ownership category
akta.pro rank

Adrenomed industry classification

Industry
Product category
Critical Care Biopharmaceuticals
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAFAC
DMPK / ADME & Bioanalysis
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

  • Septic shock therapy
  • Monoclonal antibody
  • Vascular integrity
  • Biomarker-guided medicine
  • Critical care biopharmaceuticals

Where Adrenomed is headquartered

Location

Headquarters

HQ city
Hennigsdorf
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Adrenomed business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical product revenue: Pre-revenue clinical-stage company. Enibarcimab is in late-stage clinical development for septic shock. Revenue will be generated from pharmaceutical product sales upon regulatory approval. The company is preparing for pivotal Phase III trial (BOOST) following positive FDA and EMA regulatory feedback.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Adrenomed product offering

Product offering

Core offering

Adrenomed is developing enibarcimab, a clinical-stage first-in-class non-neutralizing monoclonal antibody that binds and stabilizes Adrenomedullin (ADM) in circulation to restore and protect vascular integrity. The product targets critically ill patients with septic shock and other conditions driven by vascular leakage, with patient selection guided by a dual-biomarker (bio-ADM and DPP3) precision medicine approach. The company is currently pre-revenue and preparing for a pivotal Phase III (BOOST) trial after FDA Fast Track designation in April 2024.

Product overview

Adrenomed is a clinical-stage biopharmaceutical company developing a single lead product candidate: enibarcimab (INN, formerly Adrecizumab, HAM8101). This first-in-class monoclonal antibody targets Adrenomedullin to treat life-threatening conditions associated with loss of vascular integrity, with septic shock as the primary indication. The company employs a biomarker-guided precision medicine approach using bio-ADM (biologically active Adrenomedullin) and DPP3 (Dipeptidylpeptidase 3) to identify patients most likely to benefit from treatment. The product does not fit a traditional SaaS platform-plus-modules architecture; it is a biologic drug therapeutic.

Differentiator

Problem solved

Functional benefit

Products and services

  • Enibarcimab (HAM8101, formerly Adrecizumab) A clinical-stage, first-in-class non-neutralizing monoclonal antibody targeting Adrenomedullin (ADM) that binds and stabilizes ADM in circulation to restore vascular integrity in critically ill patients with septic shock and other conditions associated with increased vascular leakage. Administered as a single dose and being developed with a biomarker-guided precision medicine approach using bio-ADM and DPP3. Targeted at hospitals, ICUs, and acute care providers treating septic shock patients.

Quantifiable outcome

  • >60% relative reduction in 28-day mortality vs placebo in biomarker-defined (bio-ADM and DPP3) target population with sustained effect over 3 months
  • +3 more outcomes

Companies that use Adrenomed

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Adrenomed technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Adrenomed partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • University Medical Center Eppendorf (UKE) HamburgcoreImplementation/ SI/ Consulting Partner · 11 April 2022UKE Hamburg is conducting an investigator-initiated Phase II clinical trial with Adrecizumab (enibarcimab) in hospitalized COVID-19 patients with elevated adrenomedullin levels and endothelial barrier dysfunction. Prof. Dr. med. Stefan Kluge, Director of Department of Intensive Care Medicine at UKE, is leading the study.
  • sphingotec GmbHcoreStrategic or Co-development PartnerStrategic partnership for biomarker development and diagnostics. sphingotec developed sphingotest bio-ADM for measuring biologically active Adrenomedullin and co-hosts international scientific symposiums on vascular integrity with Adrenomed. Both companies founded by Dr. Andreas Bergmann. bio-ADM biomarker used for patient stratification in AdrenOSS-2 and upcoming pivotal trials. sphingotec is developing point-of-care solution on Nexus IB10 platform for bio-ADM measurement.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Adrenomed competitors and assessment

Company assessment

Direct peers

  • Inotrem: Inotrem is a clinical-stage biotech developing nangibotide, a TREM-1 inhibitor for septic shock, pursuing a similar precision-medicine biomarker strategy targeting immune/vascular dysregulation in critically ill ICU patients.
  • AM-Pharma: AM-Pharma is a clinical-stage biopharmaceutical company developing recombinant human alkaline phosphatase for the treatment of sepsis-associated acute kidney injury, targeting the same ICU/septic shock patient population as enibarcimab.
  • InflaRx: InflaRx is a clinical-stage biopharmaceutical company developing vilobelimab, an anti-C5a monoclonal antibody for severe COVID-19, hidradenitis suppurativa, and other inflammatory indications, including sepsis-related applications.
  • Atox Bio: Atox Bio is a late-stage clinical biotech developing AB103, a peptide therapeutic targeting the immune dysregulation pathway in necrotizing soft tissue infections and sepsis, with comparable septic shock development focus.
  • Endpoint Health: Endpoint Health is a precision-medicine clinical-stage company developing targeted therapies for immune-driven critical illness including sepsis and septic shock, sharing the biomarker-guided patient selection paradigm.

Emerging players

  • Enlivex Therapeutics: Enlivex Therapeutics is a clinical-stage company developing Allocetra, a cell therapy for sepsis and other inflammatory conditions, representing an alternative immunomodulatory approach to septic shock treatment.
  • CytoDyn: CytoDyn is a clinical-stage biotechnology company that has investigated leronlimab (anti-CCR5 mAb) in sepsis-related indications, representing a comparable small-cap clinical-stage sepsis therapeutics developer.

Others

  • sphingotec GmbH: sphingotec is a diagnostics company developing the bio-ADM biomarker assay used in Adrenomed's patient stratification; co-founded by Adrenomed's co-founder, making it a strategic ecosystem partner and supplier of the companion diagnostic.
  • Adrenomed's sphingotest bio-ADM diagnostic: The bio-ADM (biologically active Adrenomedullin) assay from sphingotec is the diagnostic companion that stratifies septic shock patients for enibarcimab treatment; it is the enabling technology for Adrenomed's precision-medicine approach.

Broad incumbents

  • Shionogi: Shionogi is a Japanese pharmaceutical company with established anti-infectives franchise (including cefiderocol) and active sepsis/critical-care portfolio, representing a potential large-pharma acquirer or commercial partner for enibarcimab.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Adrenomed social profiles

Digital presence

Adrenomed financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Adrenomed leadership team

Management profile

Number of profiles

Profiles10 records

Adrenomed funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Adrenomed M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adrenomed

What does Adrenomed do?

Adrenomed is developing enibarcimab, a clinical-stage first-in-class non-neutralizing monoclonal antibody that binds and stabilizes Adrenomedullin (ADM) in circulation to restore and protect vascular integrity. The product targets critically ill patients with septic shock and other conditions driven by vascular leakage, with patient selection guided by a dual-biomarker (bio-ADM and DPP3) precision medicine approach. The company is currently pre-revenue and preparing for a pivotal Phase III (BOOST) trial after FDA Fast Track designation in April 2024.

Is Adrenomed a public or private company?

Adrenomed is a private company. It is classified as venture growth investor backed and is currently operating.

When was Adrenomed founded?

Adrenomed was founded in 2009. It employs 11 to 50 people.

Where is Adrenomed based?

Adrenomed is headquartered in Hennigsdorf, Germany, in the Europe region.

How does Adrenomed make money?

One revenue line is on record: pharmaceutical product revenue.

Who are Adrenomed's main competitors?

Direct peers on record are Inotrem, AM-Pharma, InflaRx, Atox Bio and Endpoint Health. Emerging players are Enlivex Therapeutics and CytoDyn. Others are sphingotec GmbH and Adrenomed's sphingotest bio-ADM diagnostic. Shionogi is listed as a broad incumbent.

Does Adrenomed have an API?

No public API is recorded for Adrenomed.

What industry is Adrenomed in?

Adrenomed's product category is Critical Care Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireAdrenoMed Highlights Need for Personalized Therapies in Septic Shock Amid New Sepsis Guidelines and U.S. Policy InitiativeAdrenoMed AG announced it is preparing for a pivotal Phase III clinical trial of enibarcimab, its investigational therapy for septic shock, after receiving positive feedback from both the U.S. FDA and the European EMA supporting its biomarker-guided registration study design with 28-day all-cause mortality as the primary endpoint.BioSpaceAdrenoMed Highlights Need for Personalized Therapies in Septic Shock Amid New Sepsis Guidelines and U.S. Policy InitiativeAdrenoMed is preparing a pivotal biomarker-guided Phase III trial for its investigational therapy enibarcimab in septic shock, following positive feedback from the FDA and EMA. The company cites 48.9 million annual sepsis cases and a 30-40% fatality rate in septic shock, and seeks funding to advance the trial.PR NewswireSepsis Market is Projected to Boost at a CAGR of 5.1% in the US During the Forecast Period (2025-2034) | DelveInsightDelveInsight's market insights report projects the US sepsis market to grow at a CAGR of 5.1% during 2025–2034, with the market valued at USD 1.7 billion in 2024, driven by rising sepsis prevalence affecting approximately 2.4 million people and a high unmet need for advanced therapies. Hikma Pharmaceuticals received FDA approval for TYZAVAN, a first-of-its-kind ready-to-infuse vancomycin formulation, marking a key market entry in July 2025. Multiple emerging therapies including VBI-S (Vivacelle Bio), Enibarcimab (AdrenoMed), and ZEVTERA (Basilea Pharmaceutica) are advancing through clinical trials, with the anticipated launch of these candidates expected to reshape the sepsis treatment landscape and drive future market growth.PR NewswireSepsis Market is Projected to Boost at a CAGR of 5.1% in the US During the Forecast Period (2025-2034) | DelveInsightThe US sepsis market is projected to grow at a CAGR of 5.1% from 2025 to 2034, reaching USD 1.7 billion in 2024 with approximately 2.4 million people affected by the condition that year. Hikma Pharmaceuticals' TYZAVAN received US FDA approval in July 2025 and entered the sepsis market as a ready-to-infuse vancomycin formulation, with steady adoption expected due to its enhanced safety profile. Multiple companies including Vivacelle Bio, AdrenoMed, and Basilea Pharmaceutica are developing emerging sepsis therapies in clinical trials, which are anticipated to transform the market landscape in coming years.PR NewswireGlobal Sepsis Therapeutics Market Research Report 2023-2030: Market Receives Pulsating Impetus from North America, Asia-Pacific to Witness Fastest GrowthResearchAndMarkets.com published a strategic business report projecting the global sepsis therapeutics market to grow from $4.2 billion in 2022 to $7.1 billion by 2030, representing a compound annual growth rate of 6.7%. The United States market is valued at $1.4 billion while China is forecast to grow at 8.6% CAGR, the fastest among major economies, reaching $776.3 million by 2030. The report highlights cephalosporins as the dominant treatment segment projected to reach $3 billion, and identifies key industry players including GSK, F. Hoffmann-La Roche, InflaRx N.V., and Adrenomed AG among others.GlobeNewswireAdrenomed presents new findings on its precision medicine treatment for septic shock with enibarcimab during Weimar Sepsis UpdateAdrenomed presented new data on its enibarcimab treatment for septic shock, showing that patients with elevated adrenomedullin and low circulating DPP3 levels saw a >60% relative reduction in 28-day mortality versus placebo. The company is preparing a confirmatory trial based on these findings.PR NewswireGlobal Sepsis And Septic Shock Treatment Markets, 2020-2021 & 2022-2030 - Expected Launch of Novel Pipeline Molecules & Increase in R&D to Propel GrowthResearchAndMarkets.com has released a market research report projecting significant growth in the global sepsis and septic shock treatment market from 2022 to 2030, driven by rising affected populations, technological advancements in sepsis assessment, increased R&D investment, and expected launches of novel pipeline therapeutics such as MDX 1105, CYT-107, ALT-836, LB-1148, and IFX-1. The report identifies North America, led by the United States, as the current market leader due to early diagnosis capabilities, developed healthcare infrastructure, and favorable reimbursement policies, while the Asia Pacific region is forecast to show the fastest growth. Key companies profiled in the report include Adrenomed AG, Altor BioScience Corporation, Asahi Kasei Pharma, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, InflaRx GmbH, Inotrem SA, and Pfizer Inc.NatureThe key to treating sepsis and septic shock: matching treatment to causal pathophysiologyAdrenomed AG is developing Adrecizumab, a biomarker-guided antibody therapy for sepsis and septic shock targeting endothelial barrier dysfunction. The AdrenOSS-2 trial showed Adrecizumab reduced 28-day mortality from 26% to 18% in patients with elevated adrenomedullin and low DPP3. The company plans pivotal phase 2b/3 trials.UnquoteWellington, HBM lead €22m round for AdrenomedWellington Partners and HBM Healthcare Investments led a €22m financing round for Germany-based biopharmaceutical company Adrenomed. The company will use the capital to advance its lead drug candidate, Adrecizumab, and CEO Jens Schneider-Mergener stepped down, with a new candidate to be announced.